BRPI0918841A2 - derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais e composições farmacêuticas - Google Patents

derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais e composições farmacêuticas

Info

Publication number: BRPI0918841A2
Authority: BR; Brazil
Prior art keywords: dioxa; bicyclo; octane; crystals; pharmaceutical compositions
Prior art date: 2008-08-28

Application number

BRPI0918841A

Other languages

English (en)

Inventor

Benjamin Micah Collman

Vincent Mascitti

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-28

Filing date

2009-08-17

Publication date

2015-12-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41208284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918841(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-08-17 Application filed by Pfizer filed Critical Pfizer

2015-12-08 Publication of BRPI0918841A2 publication Critical patent/BRPI0918841A2/pt

2019-10-08 Publication of BRPI0918841B1 publication Critical patent/BRPI0918841B1/pt

2021-05-25 Publication of BRPI0918841B8 publication Critical patent/BRPI0918841B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BRPI0918841A 2008-08-28 2009-08-17 derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos BRPI0918841B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US9247008P	2008-08-28	2008-08-28
US61/092,470		2008-08-28
US22721209P	2009-07-21	2009-07-21
US61/227,212		2009-07-21
PCT/IB2009/053626 WO2010023594A1 (en)	2008-08-28	2009-08-17	Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives

Publications (3)

Publication Number	Publication Date
BRPI0918841A2 true BRPI0918841A2 (pt)	2015-12-08
BRPI0918841B1 BRPI0918841B1 (pt)	2019-10-08
BRPI0918841B8 BRPI0918841B8 (pt)	2021-05-25

Family

ID=41208284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0918841A BRPI0918841B8 (pt)	2008-08-28	2009-08-17	derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos

Country Status (46)

Country	Link
US (1)	US8080580B2 (pt)
EP (1)	EP2334687B9 (pt)
JP (1)	JP4825322B1 (pt)
KR (2)	KR101446454B1 (pt)
CN (2)	CN102149717B (pt)
AP (1)	AP2728A (pt)
AR (1)	AR073138A1 (pt)
AT (1)	ATE540040T1 (pt)
AU (1)	AU2009286380B2 (pt)
BR (1)	BRPI0918841B8 (pt)
CA (1)	CA2733795C (pt)
CL (1)	CL2011000394A1 (pt)
CO (1)	CO6341636A2 (pt)
CR (1)	CR20110077A (pt)
CY (2)	CY1112497T1 (pt)
DK (1)	DK2334687T5 (pt)
DO (1)	DOP2011000058A (pt)
EA (1)	EA018492B1 (pt)
EC (1)	ECSP11010854A (pt)
ES (1)	ES2380408T3 (pt)
FR (1)	FR18C1036I2 (pt)
GE (1)	GEP20135803B (pt)
HN (1)	HN2009001652A (pt)
HR (1)	HRP20120104T1 (pt)
HU (1)	HUS1800031I1 (pt)
IL (2)	IL211226A (pt)
LT (1)	LTC2334687I2 (pt)
MA (1)	MA32590B1 (pt)
ME (1)	ME01285A (pt)
MX (1)	MX2011002166A (pt)
MY (1)	MY155418A (pt)
NI (1)	NI201100043A (pt)
NL (1)	NL300943I2 (pt)
NO (1)	NO2018019I2 (pt)
NZ (1)	NZ591027A (pt)
PA (1)	PA8840801A1 (pt)
PE (1)	PE20110288A1 (pt)
PL (1)	PL2334687T3 (pt)
PT (1)	PT2334687E (pt)
RS (1)	RS52236B (pt)
SI (1)	SI2334687T1 (pt)
SV (1)	SV2011003842A (pt)
TW (1)	TWI387598B (pt)
UY (1)	UY32073A (pt)
WO (1)	WO2010023594A1 (pt)
ZA (1)	ZA201101341B (pt)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2509773C2 (ru)	2008-07-15	2014-03-20	Теракос, Инк.	Дейтерированные бензилбензольные производные и способы применения
KR101426180B1 (ko) *	2009-11-02	2014-07-31	화이자 인코포레이티드	디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
SI2547679T1 (sl)	2010-03-19	2015-12-31	Pfizer Inc.	Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja
CN102372722A (zh)	2010-08-10	2012-03-14	江苏恒瑞医药股份有限公司	C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
WO2012041898A1 (en)	2010-09-29	2012-04-05	Celon Pharma Sp. Z O.O.	Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
HUE025078T2 (en)	2010-10-29	2016-01-28	Pfizer	N1 / N2-lactam-acetyl-CoA carboxylase inhibitors
CN103965176B (zh) *	2011-02-18	2016-03-16	凯惠药业(上海)有限公司	一种芳基糖苷类化合物及其制备方法和应用
US20130345392A1 (en)	2011-03-04	2013-12-26	Pfizer Inc	Edn3-like peptides and uses thereof
MX348860B (es)	2011-04-22	2017-06-30	Pfizer	Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa.
WO2012163990A1 (en)	2011-06-03	2012-12-06	Boehringer Ingelheim International Gmbh	Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
US20140228303A1 (en) *	2011-06-13	2014-08-14	Panacea Biotec Ltd	Novel sglt inhibitors
TWI510491B (zh) *	2011-06-30	2015-12-01	Shanghai Hengrui Pharm Co Ltd	Ｃ－芳基葡萄糖苷衍生物、其製備方法及其在醫藥上的應用
CA2841757A1 (en)	2011-07-15	2013-01-24	Etzer Darout	Gpr 119 modulators
BR112014000288A2 (pt)	2011-07-22	2017-01-10	Pfizer	moduladores do receptor de glucagon de quinolinila
WO2013030713A1 (en)	2011-08-31	2013-03-07	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
JP2014530186A (ja)	2011-09-13	2014-11-17	パナセアバイオテックリミテッド	新規ｓｇｌｔ阻害剤
WO2013068439A1 (en)	2011-11-09	2013-05-16	Intervet International B.V.	4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
CN103917529B (zh)	2011-11-11	2016-08-17	辉瑞大药厂	2-硫代嘧啶酮类
AP2014007953A0 (en)	2012-04-06	2014-09-30	Pfizer	Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2013164730A1 (en)	2012-05-04	2013-11-07	Pfizer Inc.	Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
CN103570657A (zh) *	2012-07-19	2014-02-12	天津药物研究院	一类含偕二甲基的苯基c-葡萄糖苷衍生物、其制备方法和用途
US9145434B2 (en)	2012-07-26	2015-09-29	Boehringer Ingelheim International Gmbh	Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP2897964A1 (en)	2012-09-20	2015-07-29	Pfizer Inc.	Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
CN103772449B (zh) *	2012-10-26	2017-12-26	上海阳帆医药科技有限公司	C‑芳基葡萄糖苷衍生物及其制备方法与用途
CN103848806B (zh) *	2012-12-05	2016-04-06	广东东阳光药业有限公司	吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
CA2893256A1 (en)	2012-12-11	2014-06-19	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
WO2014094544A1 (zh) *	2012-12-17	2014-06-26	天津药物研究院	含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途
JP6162820B2 (ja)	2012-12-19	2017-07-12	ファイザー・インク	炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014125394A1 (en)	2013-02-13	2014-08-21	Pfizer Inc.	HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CN104045513A (zh) *	2013-03-14	2014-09-17	爱康药业有限公司	4-取代-1-氯-2-(4-氟苄基)苯及其制备方法和作为中间体在制备抗ii型糖尿病药物中的应用
PT3466431T (pt) *	2013-03-14	2024-01-26	Msd Int Gmbh	Formas cristalinas e métodos para preparação de inibidores de sglt2
PT2981269T (pt)	2013-04-04	2023-10-10	Boehringer Ingelheim Vetmedica Gmbh	Tratamento de distúrbios metabólicos em animais equinos
WO2014187365A1 (zh) *	2013-05-24	2014-11-27	四川海思科制药有限公司	氧杂双环衍生物、制备方法及其应用
WO2015027963A1 (zh) *	2013-09-02	2015-03-05	四川海思科制药有限公司	芳环类衍生物、其药物组合物及其应用
ES2605886T3 (es) *	2013-09-27	2017-03-16	Sunshine Lake Pharma Co., Ltd.	Derivados de glucopiranosilo y sus usos en medicina
JP6348582B2 (ja)	2013-10-09	2018-06-27	ファイザー・インク	プロスタグランジンｅｐ３受容体の拮抗薬
CN105611920B (zh)	2013-10-12	2021-07-16	泰拉科斯萨普有限责任公司	羟基-二苯甲烷衍生物的制备
CN111494357A (zh)	2013-12-17	2020-08-07	勃林格殷格翰动物保健有限公司	猫科动物中代谢紊乱的治疗
ES2712860T3 (es)	2014-01-23	2019-05-16	Boehringer Ingelheim Vetmedica Gmbh	Tratamiento de trastornos metabólicos en animales caninos
SI3119757T1 (en)	2014-03-17	2018-08-31	Pfizer Inc.	Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
FI3721882T3 (fi) *	2014-04-01	2024-09-24	Boehringer Ingelheim Vetmedica Gmbh	Aineenvaihduntahäiriöiden hoito hevoseläimissä
RS58597B1 (sr)	2014-04-04	2019-05-31	Pfizer	Biciklično-spojena heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora
CN106459088A (zh)	2014-04-10	2017-02-22	辉瑞公司	2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
EP3145934B1 (en)	2014-05-19	2020-11-11	Pfizer Inc	Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr
CN104031098A (zh) *	2014-06-21	2014-09-10	李友香	降糖药物
CN104017031A (zh) *	2014-06-21	2014-09-03	李友香	降血糖药物和组合物
EP3197429B1 (en)	2014-09-25	2024-05-22	Boehringer Ingelheim Vetmedica GmbH	Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
CN105461762B (zh) *	2014-09-27	2018-12-04	广东东阳光药业有限公司	吡喃葡萄糖基衍生物及其在医药上的应用
KR20170060035A (ko) *	2014-09-30	2017-05-31	지앙수 헨그루이 메디슨 컴퍼니 리미티드	나트륨 글루코스 공동운반체 2 억제제의 ｌ- 프롤린 화합물, 및 ｌ- 프롤린 화합물의 모노하이드레이트 및 결정
US10285973B2 (en) *	2014-11-10	2019-05-14	Merck Sharp & Dohme Corp.	SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
WO2016092413A1 (en)	2014-12-10	2016-06-16	Pfizer Inc.	Indole and indazole compounds that activate ampk
JP2017538769A (ja)	2014-12-22	2017-12-28	ファイザー・インク	プロスタグランジンｅｐ３受容体の拮抗薬
MA42035A (fr)	2015-05-05	2018-03-14	Pfizer	2-thiopyrimidinones
WO2016189463A1 (en) *	2015-05-25	2016-12-01	Sun Pharmaceutical Industries Limited	Ertugliflozin co-crystals and process for their preparation
CA2987179C (en)	2015-05-29	2020-08-25	Pfizer Inc.	Heterocyclic compounds as inhibitors of vanin-1 enzyme
PL3310784T3 (pl)	2015-06-17	2021-03-08	Pfizer Inc.	Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
WO2016203335A1 (en)	2015-06-18	2016-12-22	Pfizer Inc.	Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
JP2018527337A (ja)	2015-08-13	2018-09-20	ファイザー・インク	二環式縮合ヘテロアリールまたはアリール化合物
ES2865199T3 (es)	2015-08-27	2021-10-15	Pfizer	Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
BR112018003749B1 (pt)	2015-08-27	2023-10-31	Boehringer Ingelheim Vetmedica Gmbh	Composições farmacêuticas líquidas compreendendo inibidores sglt-2, kit de peças e processo para a produção da composição farmacêutica líquida
WO2017037567A1 (en)	2015-09-03	2017-03-09	Pfizer Inc.	Regulators of frataxin
JP2018531924A (ja)	2015-09-24	2018-11-01	ファイザー・インク	テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
WO2017051294A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
BR112018003489A2 (pt)	2015-09-24	2018-09-25	Pfizer	n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
DK3397631T3 (da)	2015-12-29	2021-05-25	Pfizer	Substituerede 3-azabicyclo[3.1.0]hexaner som ketohexokinase-inhibitorer
EP3404033B1 (en)	2016-01-04	2020-08-05	Jeil Pharmaceutical Co., Ltd.	C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
CN105646603A (zh) *	2016-03-01	2016-06-08	孙霖	埃格列净晶型a及制备方法
CN105646604A (zh) *	2016-03-01	2016-06-08	孙霖	埃格列净晶型b及制备方法
WO2017155841A1 (en) *	2016-03-11	2017-09-14	Merck Sharp & Dohme Corp.	Methods of treating or reducing the risk of cardiovascular events and related diseases using sglt-2 inhibitors
AU2017296338A1 (en)	2016-07-14	2019-01-03	Pfizer Inc.	Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
WO2018011721A1 (en) *	2016-07-15	2018-01-18	Granules India Limited	Novel polymorphic forms of ((1s,2s,3s,4r,5s))-2,3,4-(tris-benzyloxy)-5-(4-chloro-3-(4-ethoxy-benzyl)phenyl)-6,8-dioxa-bicyclo[3.2.1]oct-1-yl-methanol
AR109179A1 (es)	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
EA201990951A1 (ru)	2016-10-19	2019-11-29		Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
CN107382952B (zh) *	2017-07-13	2020-02-28	杭州科巢生物科技有限公司	埃格列净的制备方法及其中间体
IL274943B2 (en)	2017-11-30	2025-04-01	Idorsia Pharmaceuticals Ltd	Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases
CN107898764A (zh) *	2017-12-12	2018-04-13	威海贯标信息科技有限公司	一种埃格列净组合物
WO2019133445A1 (en)	2017-12-28	2019-07-04	Inception Ibd, Inc.	Aminothiazoles as inhibitors of vanin-1
CN107857768A (zh) *	2018-01-04	2018-03-30	威海贯标信息科技有限公司	一种埃格列净新晶型
WO2019169988A1 (zh) *	2018-03-06	2019-09-12	广东东阳光药业有限公司	埃格列净的晶型及其制备方法
CN111989103A (zh)	2018-04-17	2020-11-24	勃林格殷格翰国际有限公司	药物组合物、其治疗方法和用途
WO2019202149A1 (en)	2018-04-19	2019-10-24	Université Catholique de Louvain	Sglt2 inhibitors for the treatment of neutropenia
EP3810623A1 (en)	2018-06-25	2021-04-28	Pharmathen S.A.	A novel process for the preparation of sglt-2 inhibitors
WO2020026273A1 (en) *	2018-07-31	2020-02-06	Msn Laboratories Private Limited, R&D Center	Solid forms of ertugliflozin free base and solid dispersions comprising ertugliflozin l-pyroglutamic acid.
WO2020039394A1 (en)	2018-08-24	2020-02-27	Novartis Ag	New drug combinations
US11254660B2 (en)	2018-08-31	2022-02-22	Pfizer Inc.	Combinations for treatment of NASH/NAFLD and related diseases
WO2020102575A1 (en)	2018-11-16	2020-05-22	Inception Ibd, Inc.	Heterocyclic aminothiazoles and uses thereof
EP3972596B1 (en)	2019-05-20	2025-07-16	Pfizer Inc.	Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
WO2020261144A1 (en)	2019-06-28	2020-12-30	Pfizer Inc.	5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TW202115086A (zh)	2019-06-28	2021-04-16	美商輝瑞大藥廠	Bckdk抑制劑
JP7668259B2 (ja) *	2019-07-10	2025-04-24	サンシャイン・レイク・ファーマ・カンパニー・リミテッド	グルコピラノシル誘導体及びその使用
TWI771766B (zh)	2019-10-04	2022-07-21	美商輝瑞股份有限公司	二醯基甘油醯基轉移酶２抑制劑
AU2020394498A1 (en)	2019-11-28	2022-06-09	Boehringer Ingelheim Vetmedica Gmbh	Use of SGLT-2 inhibitors in the drying-off of non-human mammals
CN113330017B (zh) *	2019-12-19	2023-01-31	上海研健新药研发有限公司	一种SGLTs抑制剂的纯化方法及其应用
WO2021155841A1 (en)	2020-02-07	2021-08-12	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
KR20220143732A (ko)	2020-02-17	2022-10-25	베링거잉겔하임베트메디카게엠베하	고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
JP2022058085A (ja)	2020-02-24	2022-04-11	ファイザー・インク	ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CN115916197A (zh)	2020-04-22	2023-04-04	拜耳公司	用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合
FI4161927T3 (fi)	2020-06-09	2024-10-03	Pfizer	Spiroyhdisteitä melanokortiini-4-reseptorin antagonisteina ja niiden käyttöjä
WO2021260498A1 (en) *	2020-06-22	2021-12-30	Aurobindo Pharma Limited	An improved purification process for the preparation of ertugliflozin and ertugliflozin l-pyroglutamic acid co-crystal
CN114195748B (zh) *	2020-09-17	2023-11-14	上海森辉医药有限公司	一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法
JP2024525981A (ja)	2021-07-28	2024-07-12	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
WO2023006745A1 (en)	2021-07-28	2023-02-02	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
AU2022319909A1 (en)	2021-07-28	2024-02-22	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
WO2023026180A1 (en)	2021-08-26	2023-03-02	Pfizer Inc.	Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
KR20230060921A (ko)	2021-10-28	2023-05-08	유니셀랩 주식회사	에르투글리플로진의 신규 전구체
JP7704982B2 (ja)	2021-12-01	2025-07-08	ファイザー・インク	糖尿病、腎疾患、ｎａｓｈおよび心不全を処置するための分枝鎖アルファケト酸デヒドロゲナーゼキナーゼ阻害剤としての３－フェニル－１－ベンゾチオフェン－２－カルボン酸誘導体
ES3039638T3 (en)	2021-12-06	2025-10-23	Pfizer	Melanocortin 4 receptor antagonists and uses thereof
EP4490155A1 (en)	2022-03-09	2025-01-15	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
EP4508047A1 (en)	2022-04-14	2025-02-19	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
US20230381101A1 (en)	2022-05-25	2023-11-30	Boehringer Ingelheim Vetmedica Gmbh	Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
WO2024075051A1 (en)	2022-10-07	2024-04-11	Pfizer Inc.	Hsd17b13 inhibitors and/or degraders
EP4605076A1 (en)	2022-10-18	2025-08-27	Pfizer Inc.	Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024118524A1 (en)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Azaindole compounds and their use as phosphodiesterase inhibitors
EP4634180A1 (en)	2022-12-15	2025-10-22	Gasherbrum Bio, Inc.	Salts and solid forms of a compound having glp-1 agonist activity
CN120731201A (zh)	2022-12-16	2025-09-30	辉瑞公司	含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途
TW202500160A (zh)	2023-03-06	2025-01-01	德商百靈佳殷格翰維美迪加股份有限公司	用於遞送特別是包含一或多種ｓｇｌｔ—２抑制劑之液體醫藥組合物之系統及方法
AU2024250528A1 (en)	2023-04-14	2025-10-23	Pfizer Inc.	Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
TW202508455A (zh)	2023-05-24	2025-03-01	德商百靈佳殷格翰維美迪加股份有限公司	包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
WO2024240632A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
TW202539633A (zh)	2024-02-01	2025-10-16	美商輝瑞股份有限公司	葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025224599A1 (en)	2024-04-22	2025-10-30	Pfizer Inc.	Pyrrolidine-based glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2025224069A1 (en)	2024-04-23	2025-10-30	Bayer Aktiengesellschaft	Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors
WO2026013531A1 (en)	2024-07-10	2026-01-15	Pfizer Inc.	Spiro[2.5]octane compounds
CN120531728B (zh) *	2025-07-28	2025-09-19	华南农业大学	焦谷氨酸在制备抑制脂肪沉积产品中的应用

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US560230A (en) *		1896-05-19		powers
US486299A (en) *		1892-11-15		John k
US247705A (en) *		1881-09-27		William a
US838442A (en) *	1906-05-31	1906-12-11	Oscar Mietens	Compressed-air railway-train brake.
FR1499439A (fr) *	1966-09-16	1967-10-27	Electrochimie Soc	Nouveau polyol et procédé pour sa préparation
JPS5373598A (en) *	1976-12-11	1978-06-30	Teikoku Chem Ind Corp Ltd	Saccharide derivatives and process for thir preparation
JPS5911600B2 (ja) *	1981-04-30	1984-03-16	理化学研究所	３−アジド−１，６−アンヒドロ−３−デオキシ−２，４−ジ−Ｏ−ベンジル−β−Ｄ−グルコピラノ−ス及びその製造法
NZ214774A (en)	1986-01-08	1989-10-27	Nz Scientific & Ind Res	Herbicidal and/or plant growth regulatory compositions based on 1,6-anhydro-beta-hexopyranose derivatives and certain of these derivatives
US5041541A (en)	1988-05-05	1991-08-20	The Procter & Gamble Company	Functional sugar substituted with reduced calories
CN1020944C (zh)	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
CA2079544A1 (en)	1991-10-04	1993-04-05	Adam Weislaw Mazur	Cholesterol lowering compounds
DE4400464A1 (de) *	1994-01-11	1995-07-13	Bayer Ag	Endoparasitizide Mittel
DK0850948T3 (da)	1996-12-26	2002-07-29	Tanabe Seiyaku Co	Propiophenonderivater og fremgangsmåde til fremstilling deraf
US6486299B1 (en)	1998-09-28	2002-11-26	Curagen Corporation	Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en)	1998-09-30	2000-05-30	Eli Lilly And Company	Spirocyclic C-glycosides
UA71994C2 (en)	1999-08-31	2005-01-17	Kissei Pharmaceutical	Glucopyranosyloxypyrazole derivatives, a pharmaceutical composition containing these derivatives and intermediate compounds for the preparation thereof
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
AU2076701A (en)	1999-12-10	2001-06-18	Lexicon Genetics Incorporated	Novel human transporter protein and polynucleotides encoding the same
US6627611B2 (en)	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
DE10006887A1 (de)	2000-02-16	2001-09-06	Hermann Koepsell	Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern
DE10008128A1 (de)	2000-02-22	2001-08-23	Bayer Ag	Endoparasitizide Mittel
EP1270584B1 (en)	2000-03-17	2005-12-07	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
EA005994B1 (ru)	2000-09-29	2005-08-25	Киссеи Фармасьютикал Ко., Лтд.	Производные глюкопиранозилоксибензилбензола и содержащие их лекарственные композиции
JP3915116B2 (ja)	2000-11-02	2007-05-16	味の素株式会社	新規ピラゾール誘導体及びそれらを含有する糖尿病治療薬
US7053060B2 (en)	2000-11-30	2006-05-30	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
US20020081678A1 (en)	2000-12-11	2002-06-27	Gennady Merkulov	Isolated nucleic acid molecules encoding human transporter proteins, and uses thereof
KR100701437B1 (ko)	2000-12-28	2007-03-30	깃세이 야쿠힌 고교 가부시키가이샤	글루코피라노실옥시피라졸 유도체 및 그 의약 용도
EP1357186A4 (en)	2000-12-28	2005-01-26	Takeda Pharmaceutical	NEW PROTEINS AND THEIR DNAS
TWI255817B (en)	2001-02-14	2006-06-01	Kissei Pharmaceutical	Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US7087579B2 (en)	2001-02-26	2006-08-08	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivatives and medicinal use thereof
ES2350084T3 (es)	2001-02-27	2011-01-18	Kissei Pharmaceutical Co., Ltd.	Derivados de glucopiranosiloxipirazol y uso médico de los mismos.
US6936590B2 (en)	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
US20050089955A1 (en)	2001-03-27	2005-04-28	Fangcheng Gong	Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
DE60233655D1 (de)	2001-04-04	2009-10-22	Ortho Mcneil Janssen Pharm	R und retinoid x rezeptorenmodulatoren
ES2321815T3 (es)	2001-04-04	2009-06-12	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Combinacion terapeutica que comprende inhibidores de reabsorcion e glucosa y moduladores ppar.
AU2002338643A1 (en)	2001-04-10	2002-10-28	Millennium Pharmaceuticals, Inc.	68723, sodium/glucose cotransporter family members and uses therefor
DE60209343T2 (de)	2001-04-11	2006-10-26	Bristol-Myers Squibb Co.	Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
CA2672001A1 (en)	2001-04-27	2002-11-07	Ajinomoto Co., Inc.	N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
WO2002098893A1 (en)	2001-05-30	2002-12-12	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
WO2003000712A1 (en)	2001-06-20	2003-01-03	Kissei Pharmaceutical Co., Ltd.	Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JP4115105B2 (ja)	2001-07-02	2008-07-09	協和醗酵工業株式会社	ピラゾール誘導体
US7082091B2 (en) *	2001-07-31	2006-07-25	Ricoh Company, Ltd.	Information reproducing method judging a multivalued level of a present cell by referring to judged multivalued levels of a preceding cell and an ensuing cell
KR100945455B1 (ko)	2002-03-22	2010-03-05	깃세이 야쿠힌 고교 가부시키가이샤	글루코피라노실옥시벤질 벤젠 유도체의 결정
US20070059356A1 (en)	2002-05-31	2007-03-15	Almarsson Oern	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE10225844A1 (de)	2002-06-04	2003-12-18	Lang Florian	sgk und nedd als diagnostische und therapeutische targets
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
JP4540475B2 (ja)	2002-08-08	2010-09-08	キッセイ薬品工業株式会社	ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
BR0310006A (pt)	2002-08-09	2005-02-15	Taisho Pharmaceutical Co Ltd	Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
DE10237085A1 (de)	2002-08-09	2004-02-19	Bioagency Ag	Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
JP2004137245A (ja)	2002-08-23	2004-05-13	Kissei Pharmaceut Co Ltd	ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
EP1557178A4 (en)	2002-10-29	2009-07-22	Takeda Pharmaceutical	USE OF SGLT HOMOLOG
JP4651934B2 (ja)	2002-12-04	2011-03-16	キッセイ薬品工業株式会社	ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
CA2507665A1 (en)	2002-12-04	2004-06-17	Kissei Pharmaceutical Co., Ltd.	Preventive or remedy for diseases caused by hyperglycemia
DE10258007B4 (de)	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de)	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CA2509835A1 (en)	2002-12-25	2004-07-15	Kissei Pharmaceutical Co., Ltd.	Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
BR0317929A (pt)	2003-01-03	2006-04-11	Bristol Myers Squibb Co	métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
CN1771334A (zh)	2003-03-07	2006-05-10	施瑞修德制药公司	用于确定肿瘤对抗肿瘤药剂的治疗的敏感性的方法
WO2004080990A1 (ja)	2003-03-14	2004-09-23	Astellas Pharma Inc.	Ｃ－グリコシド誘導体又はその塩
JP2004300102A (ja)	2003-03-31	2004-10-28	Kissei Pharmaceut Co Ltd	縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
US7439232B2 (en)	2003-04-01	2008-10-21	Taisho Pharmaceutical Co., Ltd.	Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
WO2004089966A1 (ja)	2003-04-01	2004-10-21	Taisho Pharmaceutical Co., Ltd.	選択的なヘテロアリール５－チオ－β－Ｄ－アルドヘキソピラノシドの製造法
AU2003902263A0 (en)	2003-05-12	2003-05-29	Fujisawa Pharmaceutical Co., Ltd.	Monosaccharide compounds
WO2004106352A1 (ja)	2003-05-29	2004-12-09	Taisho Pharmaceutical Co., Ltd.	アルドヘキソピラノース中間体の製造法
JP2004359630A (ja)	2003-06-06	2004-12-24	Yamanouchi Pharmaceut Co Ltd	ジフルオロジフェニルメタン誘導体及びその塩
JP4708187B2 (ja)	2003-06-20	2011-06-22	キッセイ薬品工業株式会社	ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
UA86042C2 (en)	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
EA015104B1 (ru)	2003-08-01	2011-06-30	Мицубиси Танабе Фарма Корпорейшн	Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
US7375090B2 (en)	2003-08-26	2008-05-20	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US7371732B2 (en)	2003-12-22	2008-05-13	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
JP2005247834A (ja)	2004-02-04	2005-09-15	Taisho Pharmaceut Co Ltd	ナトリウム依存性グルコース供輸送体２の活性阻害剤
WO2005085265A1 (ja)	2004-03-04	2005-09-15	Kissei Pharmaceutical Co., Ltd.	縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
BRPI0508259A (pt)	2004-03-04	2007-07-31	Kissei Pharmaceutical	derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
US7375113B2 (en)	2004-03-04	2008-05-20	Kissei Pharmaceutical Co., Ltd.	Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
DE102004012676A1 (de) *	2004-03-16	2005-10-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP4181605B2 (ja)	2004-03-16	2008-11-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
WO2005095429A1 (ja)	2004-03-31	2005-10-13	Kissei Pharmaceutical Co., Ltd.	フェノール誘導体、それを含有する医薬組成物及びその医薬用途
TW200602335A (en)	2004-03-31	2006-01-16	Kissei Pharmaceutical	Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
JPWO2005095372A1 (ja)	2004-03-31	2008-02-21	キッセイ薬品工業株式会社	ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
DE102004028241B4 (de)	2004-06-11	2007-09-13	Sanofi-Aventis Deutschland Gmbh	Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en)	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US20070293690A1 (en)	2004-07-08	2007-12-20	Hiroshi Tomiyama	Process for Production of Azulene Derivatives and Intermediates for the Synthesis of the Same
DE102004034690A1 (de)	2004-07-17	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP5010918B2 (ja)	2004-07-21	2012-08-29	キッセイ薬品工業株式会社	肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
TW200606129A (en)	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (de)	2004-07-27	2007-04-18	Boehringer Ingelheim International GmbH	D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de)	2004-08-11	2006-02-23	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es)	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2006117651A (ja)	2004-09-27	2006-05-11	Taisho Pharmaceut Co Ltd	Ｓｇｌｔ２の活性阻害剤
MX2007003785A (es)	2004-09-29	2007-07-12	Kissei Pharmaceutical	Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo.
DE102004048388A1 (de)	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006054629A1 (ja)	2004-11-18	2006-05-26	Kissei Pharmaceutical Co., Ltd.	１－置換－３－（β－Ｄ－グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬
JP2008007405A (ja)	2004-12-07	2008-01-17	Takeda Chem Ind Ltd	カルボキサミド誘導体
JP2008524162A (ja)	2004-12-16	2008-07-10	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
TW200637839A (en)	2005-01-07	2006-11-01	Taisho Pharmaceutical Co Ltd	1-thio-d-glucitol derivatives
TW200637869A (en)	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es)	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
DE602006019825D1 (de)	2005-02-15	2011-03-10	Kissei Pharmaceutical	1-substituierte-7-(b-d-glycopyranosyloxy)(aza)indolverbindung und pharmazeutikum, das diese enthält
ATE445608T1 (de)	2005-02-23	2009-10-15	Boehringer Ingelheim Int	Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
WO2006108582A2 (en)	2005-04-15	2006-10-19	Cenix Bioscience Gmbh	Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis
ATE453656T1 (de)	2005-04-15	2010-01-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
WO2006115137A1 (ja)	2005-04-22	2006-11-02	Kissei Pharmaceutical Co., Ltd.	２－アミノベンズイミダゾール誘導体及びその医薬用途
US20070009615A1 (en)	2005-04-29	2007-01-11	Litao Zhong	Compositions and methods for controlling glucose uptake
US7723309B2 (en)	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk)	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en)	2005-06-29	2007-01-04	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en)	2005-07-07	2007-07-16	Astellas Pharma Inc	A crystalline choline salt of an azulene derivative
AR054871A1 (es)	2005-07-27	2007-07-25	Boehringer Ingelheim Int	Derivados de (hetero)cicloalquiletinil-bencil)-benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, sus uso y proceso para su fabricacion
US20070036874A1 (en)	2005-08-05	2007-02-15	Litao Zhong	Compositions and methods for controlling glucose and lipid uptake from foods
JP5175191B2 (ja)	2005-08-30	2013-04-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
TW200745075A (en)	2005-09-08	2007-12-16	Boehringer Ingelheim Int	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
US20070099237A1 (en)	2005-10-31	2007-05-03	The Regents Of The University Of Michigan	Reaction co-crystallization of molecular complexes or co-crystals
TWI370818B (en)	2006-04-05	2012-08-21	Astellas Pharma Inc	Cocrystal of c-glycoside derivative and l-proline
JP2009167103A (ja)	2006-05-02	2009-07-30	Taisho Pharmaceutical Co Ltd	ピラゾリル５−チオグリコシド化合物
JP2009167104A (ja)	2006-05-02	2009-07-30	Taisho Pharmaceutical Co Ltd	フェニル５−チオグリコシド化合物
PE20080697A1 (es)	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2019679B1 (en) *	2006-05-23	2018-06-20	Theracos, Inc.	Glucose transport inhibitors and methods of use
DE102006028862A1 (de)	2006-06-23	2007-12-27	Merck Patent Gmbh	3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en)	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
BRPI0713058A2 (pt)	2006-06-29	2012-04-10	Taisho Pharmaceutical Co., Ltd.	composto de 1-tioglucitol de c-fenila
TWI432446B (zh)	2006-07-27	2014-04-01	Chugai Pharmaceutical Co Ltd	稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
JP2008050353A (ja)	2006-07-27	2008-03-06	Mitsubishi Tanabe Pharma Corp	医薬組成物
TWI418556B (zh)	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
TWI403516B (zh) *	2006-07-27	2013-08-01	Chugai Pharmaceutical Co Ltd	To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
US20080027014A1 (en)	2006-07-28	2008-01-31	Tanabe Seiyaku Co., Ltd.	Novel SGLT inhibitors
TW200817424A (en)	2006-08-04	2008-04-16	Daiichi Sankyo Co Ltd	Benzylphenyl glucopyranoside derivatives
CN101121148B (zh)	2006-08-08	2010-05-12	中国科学院大连化学物理研究所	一种含分子筛的流化反应催化剂直接成型方法
US8133420B2 (en) *	2006-08-09	2012-03-13	Dow Global Technologies Llc	Multi-segment expandable polymer compositions which expand in a controllable direction
US8039441B2 (en)	2006-08-15	2011-10-18	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
JP5372759B2 (ja)	2006-09-21	2013-12-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル−置換ジフルオロベンジル−ベンゼン誘導体、該化合物を含有する医薬品及びその使用と調製方法
MX2009003927A (es)	2006-10-13	2009-04-23	Chugai Pharmaceutical Co Ltd	Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
DE102006048728A1 (de)	2006-10-16	2008-04-17	Merck Patent Gmbh	3-Amino-imidazo{1,2-a]pyridinderivate
EP2086991A1 (en)	2006-10-27	2009-08-12	Boehringer Ingelheim International GmbH	CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
US7879806B2 (en)	2006-11-06	2011-02-01	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture
WO2008115574A1 (en)	2007-03-21	2008-09-25	Reliant Pharmaceuticals, Inc.	Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
TW200904454A (en)	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
JP5653213B2 (ja)	2007-07-26	2015-01-14	レクシコンファーマシューティカルズインコーポレイテッド	ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物
PE20090603A1 (es)	2007-08-16	2009-06-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
BRPI0815708B8 (pt)	2007-08-23	2021-05-25	Theracos Sub Llc	composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101503399B (zh) *	2008-02-04	2012-06-27	白鹭医药技术（上海）有限公司	C-芳基葡萄糖苷sglt2抑制剂

2009
- 2009-08-17 EP EP09786960A patent/EP2334687B9/en active Active
- 2009-08-17 MX MX2011002166A patent/MX2011002166A/es active IP Right Grant
- 2009-08-17 NZ NZ591027A patent/NZ591027A/xx unknown
- 2009-08-17 AP AP2011005616A patent/AP2728A/xx active
- 2009-08-17 WO PCT/IB2009/053626 patent/WO2010023594A1/en not_active Ceased
- 2009-08-17 PE PE2011000205A patent/PE20110288A1/es active IP Right Grant
- 2009-08-17 CA CA2733795A patent/CA2733795C/en active Active
- 2009-08-17 ME MEP-2011-45A patent/ME01285A/me unknown
- 2009-08-17 HR HR20120104T patent/HRP20120104T1/hr unknown
- 2009-08-17 RS RS20120084A patent/RS52236B/sr unknown
- 2009-08-17 GE GEAP200912121A patent/GEP20135803B/en unknown
- 2009-08-17 AU AU2009286380A patent/AU2009286380B2/en active Active
- 2009-08-17 JP JP2011524489A patent/JP4825322B1/ja active Active
- 2009-08-17 KR KR1020137025842A patent/KR101446454B1/ko active Active
- 2009-08-17 EA EA201100266A patent/EA018492B1/ru active Protection Beyond IP Right Term
- 2009-08-17 CN CN200980135661.2A patent/CN102149717B/zh active Active
- 2009-08-17 PT PT09786960T patent/PT2334687E/pt unknown
- 2009-08-17 AT AT09786960T patent/ATE540040T1/de active
- 2009-08-17 KR KR1020117006928A patent/KR101338540B1/ko active Active
- 2009-08-17 ES ES09786960T patent/ES2380408T3/es active Active
- 2009-08-17 BR BRPI0918841A patent/BRPI0918841B8/pt active IP Right Grant
- 2009-08-17 SI SI200930161T patent/SI2334687T1/sl unknown
- 2009-08-17 MY MYPI2011000903A patent/MY155418A/en unknown
- 2009-08-17 PL PL09786960T patent/PL2334687T3/pl unknown
- 2009-08-17 DK DK09786960.6T patent/DK2334687T5/da active
- 2009-08-17 CN CN201310128399.7A patent/CN103497199B/zh active Active
- 2009-08-24 US US12/546,306 patent/US8080580B2/en active Active
- 2009-08-26 UY UY0001032073A patent/UY32073A/es active IP Right Grant
- 2009-08-26 HN HN2009001652A patent/HN2009001652A/es unknown
- 2009-08-26 AR ARP090103280A patent/AR073138A1/es active IP Right Grant
- 2009-08-27 TW TW098128894A patent/TWI387598B/zh active
- 2009-08-27 PA PA20098840801A patent/PA8840801A1/es unknown
2011
- 2011-02-09 CR CR20110077A patent/CR20110077A/es unknown
- 2011-02-14 IL IL211226A patent/IL211226A/en active Protection Beyond IP Right Term
- 2011-02-17 SV SV2011003842A patent/SV2011003842A/es unknown
- 2011-02-18 ZA ZA2011/01341A patent/ZA201101341B/en unknown
- 2011-02-21 DO DO2011000058A patent/DOP2011000058A/es unknown
- 2011-02-23 CO CO11022222A patent/CO6341636A2/es active IP Right Grant
- 2011-02-23 CL CL2011000394A patent/CL2011000394A1/es unknown
- 2011-02-24 NI NI201100043A patent/NI201100043A/es unknown
- 2011-02-28 EC EC2011010854A patent/ECSP11010854A/es unknown
- 2011-02-28 MA MA33651A patent/MA32590B1/fr unknown
2012
- 2012-03-15 CY CY20121100280T patent/CY1112497T1/el unknown
2015
- 2015-01-19 IL IL236804A patent/IL236804B/en active IP Right Grant
2018
- 2018-06-26 NO NO2018019C patent/NO2018019I2/no unknown
- 2018-06-27 NL NL300943C patent/NL300943I2/nl unknown
- 2018-07-13 HU HUS1800031C patent/HUS1800031I1/hu unknown
- 2018-08-21 LT LTPA2018510C patent/LTC2334687I2/lt unknown
- 2018-08-24 FR FR18C1036C patent/FR18C1036I2/fr active Active
- 2018-09-03 CY CY2018024C patent/CY2018024I1/el unknown

Also Published As

Publication number	Publication date
SI2334687T1 (sl)	2012-03-30
TWI387598B (zh)	2013-03-01
EA018492B1 (ru)	2013-08-30
FR18C1036I1 (pt)	2018-10-05
RS52236B (sr)	2012-10-31
HN2009001652A (es)	2012-02-13
UY32073A (es)	2010-03-26
PE20110288A1 (es)	2011-05-26
ME01285A (me)	2013-06-20
BRPI0918841B1 (pt)	2019-10-08
ZA201101341B (en)	2011-11-30
LTPA2018510I1 (lt)	2018-09-25
JP4825322B1 (ja)	2011-11-30
US20100056618A1 (en)	2010-03-04
DK2334687T3 (da)	2012-04-16
IL211226A0 (en)	2011-04-28
FR18C1036I2 (fr)	2020-07-24
PL2334687T3 (pl)	2012-05-31
AP2011005616A0 (en)	2011-04-30
KR20130116078A (ko)	2013-10-22
DK2334687T5 (da)	2012-09-10
ES2380408T9 (es)	2013-02-22
BRPI0918841B8 (pt)	2021-05-25
NL300943I2 (nl)	2018-08-07
LTC2334687I2 (lt)	2019-09-10
AR073138A1 (es)	2010-10-13
HK1156616A1 (en)	2012-06-15
AP2728A (en)	2013-08-31
DOP2011000058A (es)	2011-03-15
AU2009286380B2 (en)	2011-09-15
CL2011000394A1 (es)	2011-06-17
MY155418A (en)	2015-10-15
CO6341636A2 (es)	2011-11-21
US8080580B2 (en)	2011-12-20
NO2018019I1 (no)	2018-06-26
CY2018024I2 (el)	2019-11-27
PA8840801A1 (es)	2010-04-21
EA201100266A1 (ru)	2011-10-31
ECSP11010854A (es)	2011-03-31
IL236804B (en)	2019-06-30
AU2009286380A1 (en)	2010-03-04
CA2733795C (en)	2013-12-31
MA32590B1 (fr)	2011-08-01
CA2733795A1 (en)	2010-03-04
CN102149717A (zh)	2011-08-10
CN103497199A (zh)	2014-01-08
MX2011002166A (es)	2011-04-07
KR20110045093A (ko)	2011-05-03
CY2018024I1 (el)	2019-11-27
NO2018019I2 (no)	2019-02-19
NZ591027A (en)	2012-11-30
HK1193606A1 (en)	2014-09-26
IL211226A (en)	2015-02-26
HUS1800031I1 (hu)	2018-08-28
CN103497199B (zh)	2015-04-29
TW201014863A (en)	2010-04-16
PT2334687E (pt)	2012-04-13
GEP20135803B (en)	2013-04-10
WO2010023594A1 (en)	2010-03-04
CY1112497T1 (el)	2015-12-09
AU2009286380A8 (en)	2011-03-17
NI201100043A (es)	2011-08-05
KR101338540B1 (ko)	2013-12-06
ES2380408T3 (es)	2012-05-11
EP2334687A1 (en)	2011-06-22
EP2334687B1 (en)	2012-01-04
IL236804A0 (en)	2015-03-31
HRP20120104T1 (hr)	2012-02-29
JP2012500842A (ja)	2012-01-12
EP2334687B9 (en)	2012-08-08
ATE540040T1 (de)	2012-01-15
KR101446454B1 (ko)	2014-10-06
CR20110077A (es)	2011-03-09
SV2011003842A (es)	2011-03-23
CN102149717B (zh)	2014-05-14

Publication	Publication Date	Title
BRPI0918841A2 (pt)	2015-12-08	derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais e composições farmacêuticas
BRPI0915897A2 (pt)	2015-11-03	compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
IL206395A (en)	2015-04-30	N- Heterocyclic-7-Oxo-6-Sulphoxy-6,1-Diazabicyclo [1.2.3] Octane-2-Carboxamides and Pharmaceuticals Containing Them
BRPI0720124A2 (pt)	2014-03-04	Composições farmacêuticas e seus métodos de uso.
IL203915A (en)	2016-04-21	Annotations of 2-Benzylphenyl-6-Hydroxymethyl-Tetrahydro-2 H-Pyrene-3,4,5-Triol
DK1962873T3 (da)	2013-08-26	Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
BRPI0922435A2 (pt)	2018-09-11	"composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
BRPI0813455A2 (pt)	2014-12-23	Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.
BRPI0819047A2 (pt)	2015-05-05	"composição, seu processo de preparação e seus usos"
BRPI0910503A2 (pt)	2015-09-29	compostos, composições farmacêuticas e respectivos usos.
BRPI1010621A2 (pt)	2016-06-21	derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI0718688A2 (pt)	2013-12-24	Composições de baixa irritação e métodos para preparar as mesmas.
SI2200588T1 (sl)	2019-08-30	Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
AP3099A (en)	2015-01-31	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol de derivatives
IL206808A (en)	2015-08-31	Indolyl-pyridone history, their pharmaceutical preparations and their uses
IL193772A0 (en)	2009-08-03	4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
IL213570A (en)	2015-10-29	History 8 - Alkoxy - s - Triazolo [5,1 - a] pyridine and pharmaceutical preparations containing them
BRPI0915552A2 (pt)	2017-06-20	derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0818690A2 (pt)	2015-04-14	Derivados de quinazolinediona, sua preparação e seus usos terapêuticos.
FR2917409B1 (fr)	2010-06-04	Derives de dinitropyrazoles, leur preparation et les compositions energetiques les renfermant.
PL2358702T3 (pl)	2013-12-31	Związki piperydynowe, zawierająca je kompozycja farmaceutyczna oraz ich zastosowanie
BRPI0912118A2 (pt)	2015-11-03	composto, composição farmacêutica, e, intermediário sintético
EP2166015A4 (en)	2012-09-05	LINCOSAMIDE DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING ACTIVE SUBSTANCE
BRPI0813937A2 (pt)	2014-12-30	Derivado de 17beta-ciano-19-nor-andros-4-eno, seu uso e medicamentos contendo o derivado
EP1916251A4 (en)	2010-09-08	ERIANINE SALTS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-01-08	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-05-07	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-08-20	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-10-08	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-08-29	B25G	Requested change of headquarter approved	Owner name: PFIZER INC. (US)